Vital NICE nod for Jazz’s Epidyolex
UK-wide therapy for patients who have seizures linked to tuberous sclerosis complex
Read More
Tag: Epidyolex
UK approval for Epidyolex to treat seizures from tuberous sclerosis
Approval represents a new indication for GW’s cannabidiol in the UK
Read More
GW Pharma’s Epidyolex scores new EU indication
Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis complex
Read More
SMC accepts 14 new medicines for use by NHS Scotland
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read More
UK Home Office loosens restrictions on GW’s Epidyolex
The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
Read More
NHS fast-tracks access to Epidyolex for severe epilepsy
Doctors will be able to prescribe the drug from January 6
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
